Futura Medical plc (FUM) 2017年年度报告「LSE」.pdf

1、25996 6 April 2018 10:16 AM Proof 6Futura Medical plcAnnual Report and Accounts 2017EXPERTS IN TRANSDERMAL DELIVERYFutura Medical AR2017.indd 24/6/2018 10:22:36 AM25996 6 April 2018 10:16 AM Proof 6About Futura MedicalWhat we doFuturas innovation strategy applies advanced science to develop products

2、 with compelling commercial potential using our advanced proprietary transdermal technology.Our key strengthsTechnological strengthsWe have strong IP on all products under development.Our expertise is in transdermal delivery.Commercial strengthsWe are focused on products for which there are substant

3、ial market opportunities.We currently have agreements with a number of key industry players.We specialise within the growing consumer healthcare sector.Financial strengthsWe maintain a high ratio of research and development spend relative to administrative costs and a virtual organisational structur

4、e.Contents About Futura MedicalOur Strategy 01Highlights 02Our Business Model 03Our Expertise 04Our Pipeline 05GovernanceChairmans and Chief Executives Review 06Strategic Report 11Board of Directors 17Remuneration Report 19Corporate Governance 24Directors Report 27Independent Auditors Report to the

5、members of Futura Medical plc 29Financial StatementsConsolidated Statement of Comprehensive Income 33Consolidated Statement of Changes in Equity 34Consolidated Statement of Financial Position 35Consolidated Statement of Cash Flows 36Notes to the Consolidated Financial Statements 37Parent Company Bal

6、ance Sheet 57Parent Company Statement of Changes in Equity 58Notes to the Parent Company Financial Statements 59Company Information Futura Medical AR2017.indd 34/6/2018 10:22:37 AMOur StrategyFuturas innovation strategy applies advanced science to develop products with compelling commercial potentia